The recent surge in funding into specialized pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the possibility for blockbuster treatments and substantial returns is clear, the linked risks are also notable. Many o